<DOC>
	<DOCNO>NCT01572597</DOCNO>
	<brief_summary>Compare efficacy safety 10-day triple therapy ( rabeprazole , clarithromycin amoxicillin ) plus N-acetylcystein versus 10-day concomitant therapy ( rabeprazole , clarithromycin , amoxicillin metronidazole ) re-eradication gastric Helicobacter pylorus infection .</brief_summary>
	<brief_title>Increased Re-eradication Rate Helicobacter Pylori Adding N-acetylcystein Metronidazole Triple Therapy</brief_title>
	<detailed_description>Background : Antimicrobial resistance decrease eradication rate common used triple therapy Helicobacter pylorus infection ( le 80 % ) . Such treatment patient previously treatment failure , retreatment eradication rate le 50 % . Some study show Helicobacter pylorus form biofilm prevent entry antibiotic , N-acetylcystein helpful dissolve biofilm . Objective : To determine eradication rate common use triple therapy add N-acetylcystein second line treatment adult infect Helicobacter pylori Eastern Taiwan . Design : Randomized , open-label , prospective control trial . Patients : previously fail primary treatment eradication still infect Helicobacter pylorus . Measurements : 13C-urea breath test , upper endoscopy , histologic evaluation , rapid urease test , bacterial culture , assessment antibiotic resistance CYP2C19 genotype host . Intervention : patient Helicobacter pylori eradication treatment failure recruit randomly assign receive one follow therapeutic scheme : 1 ) study group : rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + N-acetylcystein 0.6g bid 10 day ; 2 ) control group : rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid 10 day . Repeat upper endoscopy histologic evaluation , rapid urease test 13C-urea breath test 4 week treatment ass treatment result . The influence hybrid therapy antibiotic resistance Helicobacter pylorus CYP2C19 genotype host determine . Expected result : The new second line treatment eradication Helicobacter pylorus effective , determine relation antibiotic resistance Helicobacter pylorus CYP2C19 genotype host treatment result .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Patient treatment Helicobacter pylorus eradication . Still clinically evidence gastric Helicobacter pylorus infection . woman breast feeding pregnancy . allergy drug use study . never treat H. pylorus . intolerance fructose , lactose . patient hematologic , brain spinal disorder . patient 20 year old . patient malignancy decompensated function vital organ .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>antibiotic resistance</keyword>
	<keyword>N-acetylcystein</keyword>
	<keyword>biofilm</keyword>
	<keyword>second-line eradication treatment</keyword>
</DOC>